MaaT Pharma Launches Phase 2 Trial for NSCLC Patients

MaaT Pharma has initiated patient randomization for the IMMUNOLIFE Phase 2 study. The trial, sponsored by Gustave Roussy, investigates the potential of MaaT033 in combination with Cemiplimab to improve disease control in advanced non-small cell lung cancer (NSCLC) patients with antibiotic-induced dysbiosis. Patients, who show resistance to PD-1/PD-L1 blockade post-antibiotic treatment, are divided into groups to receive either MaaT033 with Cemiplimab or the best investigator's choice.

The study involves 162 patients across 14 centers in France and aims for primary results in late 2030. An interim analysis is expected around mid-2027. The trial seeks to explore microbiome therapy's role in enhancing responses to immune checkpoint inhibitors, with insights anticipated to guide the development of MaaT Pharma’s microbiome therapies, including the MaaT034 program.

The IMMUNOLIFE consortium, funded by the French National Research Agency, includes institutions like Gustave Roussy and aims to combat primary ICI resistance in NSCLC patients post-antibiotic exposure.